SC

Sahil Chadha

Director Director DIN 08350103
DIN 08350103 First appointment Feb 2019 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Feb 2019
Shareholding value β€’β€’β€’β€’ Premium profile

About Sahil Chadha

Data last updated:

Sahil Chadha was a Director at Smithbraun Laboratories Private Limited (2019–2025) and Director at Schwazmith Farmaceuticos Private Limited (from 2022). The companies operate in Pharma.

DIN 08350103
Primary Designation Director
Industry Pharma
First Appointment 20 Feb 2019
Oldest Company Age 4 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Feb 20192019₹9.7 Lakh (FY 2024)Active
Director17 Jun 20222022Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Schwazmith Farmaceuticos Private Limited
Smithbraun Laboratories Private Limited
Premium access

Shareholding and investment profile for Sahil Chadha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sahil Chadha

Sahil Chadha was first appointed on 20 Feb 2019 as Director at Smithbraun Laboratories Private Limited. The most recent appointment on record is 17 Jun 2022 at Schwazmith Farmaceuticos Private Limited.

Sahil Chadha held 2 earlier board appointments: Smithbraun Laboratories Private Limited (Director, 20 Feb 2019 to 14 Aug 2025); Schwazmith Farmaceuticos Private Limited (Director, from 17 Jun 2022).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available